PURPOSE: There is growing interest in developing cellular immune therapies for glioblastoma multiforme, but little is known about tumor-specific T-cell responses. A glioblastoma multiforme-specific T-cell assay was developed using monocyte-derived dendritic cells to present tumor antigens from the established glioblastoma multiforme cell line U118. EXPERIMENTAL DESIGN: Peripheral blood mononuclear cells (PBMC) and tumor cells were obtained from nine patients with newly diagnosed brain tumors: five glioblastoma multiforme, two oligodendroglioma, one ependymoma, and one astrocytoma. PBMCs were incubated overnight with autologous tumor cells or autologous dendritic cells loaded with a U118 cell lysate, and responses were detected by IFN-gamma ELISPOT and cytokine flow cytometry assays. RESULTS: PBMCs from all glioblastoma multiforme patients exhibited IFN-gamma responses to autologous tumor but not to HLA-mismatched U118 cells. Glioblastoma multiforme-specific IFN-gamma responses were primarily mediated by CD8+ T cells and represented approximately 2% of total CD8+ T cells. Additionally, all glioblastoma multiforme patients responded to autologous dendritic cells loaded with U118 lysate but not with low-grade astrocytoma cell lysates. PBMCs from four patients with other brain tumor types and one normal donor failed to respond to U118 lysate-loaded autologous dendritic cells. These data indicate that the IFN-gamma responses to U118 lysate-loaded autologous dendritic cells are glioblastoma multiforme specific. Moreover, PBMCs stimulated 1 to 2 weeks with U118 lysate-loaded dendritic cells exhibited MHC class I-restricted cytotoxicity against autologous tumor cells. CONCLUSIONS: Glioblastoma multiforme patients exhibit circulating tumor-specific CD8+ T cells that recognize shared tumor antigens from the glioblastoma multiforme cell line U118. These data show that glioblastoma multiformes are immunogenic and support the development of immunotherapy trials.
PURPOSE: There is growing interest in developing cellular immune therapies for glioblastoma multiforme, but little is known about tumor-specific T-cell responses. A glioblastoma multiforme-specific T-cell assay was developed using monocyte-derived dendritic cells to present tumor antigens from the established glioblastoma multiforme cell line U118. EXPERIMENTAL DESIGN: Peripheral blood mononuclear cells (PBMC) and tumor cells were obtained from nine patients with newly diagnosed brain tumors: five glioblastoma multiforme, two oligodendroglioma, one ependymoma, and one astrocytoma. PBMCs were incubated overnight with autologous tumor cells or autologous dendritic cells loaded with a U118 cell lysate, and responses were detected by IFN-gamma ELISPOT and cytokine flow cytometry assays. RESULTS: PBMCs from all glioblastoma multiformepatients exhibited IFN-gamma responses to autologous tumor but not to HLA-mismatched U118 cells. Glioblastoma multiforme-specific IFN-gamma responses were primarily mediated by CD8+ T cells and represented approximately 2% of total CD8+ T cells. Additionally, all glioblastoma multiformepatients responded to autologous dendritic cells loaded with U118 lysate but not with low-grade astrocytoma cell lysates. PBMCs from four patients with other brain tumor types and one normal donor failed to respond to U118 lysate-loaded autologous dendritic cells. These data indicate that the IFN-gamma responses to U118 lysate-loaded autologous dendritic cells are glioblastoma multiforme specific. Moreover, PBMCs stimulated 1 to 2 weeks with U118 lysate-loaded dendritic cells exhibited MHC class I-restricted cytotoxicity against autologous tumor cells. CONCLUSIONS:Glioblastoma multiformepatients exhibit circulating tumor-specific CD8+ T cells that recognize shared tumor antigens from the glioblastoma multiforme cell line U118. These data show that glioblastoma multiformes are immunogenic and support the development of immunotherapy trials.
Authors: Larry A Harshyne; Brian J Nasca; Lawrence C Kenyon; David W Andrews; D Craig Hooper Journal: Neuro Oncol Date: 2015-07-14 Impact factor: 12.300
Authors: Chris A Learn; Peter M Grossi; Robert J Schmittling; Weihua Xie; Duane A Mitchell; Isaac Karikari; ZhengZheng Wei; Holly Dressman; John H Sampson Journal: J Neuroimmunol Date: 2006-11-29 Impact factor: 3.478
Authors: Marian Christoph Neidert; Oliver Schoor; Claudia Trautwein; Nico Trautwein; Lisa Christ; Arthur Melms; Jürgen Honegger; Hans-Georg Rammensee; Christel Herold-Mende; Pierre-Yves Dietrich; Stefan Stevanović Journal: J Neurooncol Date: 2012-12-23 Impact factor: 4.130
Authors: David A Reardon; Kai W Wucherpfennig; Gordon Freeman; Catherine J Wu; E Antonio Chiocca; Patrick Y Wen; William T Curry; Duane A Mitchell; Peter E Fecci; John H Sampson; Glenn Dranoff Journal: Expert Rev Vaccines Date: 2013-06 Impact factor: 5.217
Authors: Tiziano Di Tomaso; Stefania Mazzoleni; Ena Wang; Gloria Sovena; Daniela Clavenna; Alberto Franzin; Pietro Mortini; Soldano Ferrone; Claudio Doglioni; Francesco M Marincola; Rossella Galli; Giorgio Parmiani; Cristina Maccalli Journal: Clin Cancer Res Date: 2010-01-26 Impact factor: 12.531